CLIN.L Share News (CLIN)

CLIN.L Information

There is currently no data for CLIN

Thursday broker round-up

Thu, 28th May 2020 13:34

(Sharecast News) - Provident Financial: RBC Capital Markets reiterates sector performer with a target price of 195p.

IWG: Berenberg reiterates hold with a target price of 130p.

Jadestone Energy: Berenberg reiterates buy with a target price of 105p.

PayPoint: Canaccord reiterates buy with a target price of 825p.

Charles Stanley: Canaccord reiterates hold with target price of 307p.

Halfords: Peel Hunt reiterates buy with a target price of 210p.

Draper Esprit: Peel Hunt reiterates buy with a target price of 634p.

IWG: Peel Hunt reiterates hold with a target price of 239p.

Boohoo: Peel Hunt reiterates buy with a target price of 425p.

Clinigen: Liberum reiterates buy with a target price of 1,050p.

British Land: Deutsche Bank reiterates hold with a target price of 475p.

Daily Mail: JP Morgan reiterates overweight with a target price of 800p.

More News

14 Jul 2020 09:07

Clinigen FY revenues continue to rise, profit growth slowed by Covid-19

(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pandemic and the launch of a low-cost competitor to its Foscavir drug.

13 Jul 2020 16:29

Clinigen gets orphan drug designation for 'aldesleukin' in the US

(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted orphan drug designation for 'aldesleukin', in the treatment of amyotrophic lateral sclerosis (ALS).

13 Jul 2020 13:48

Monday broker round-up

(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p

13 Jul 2020 08:41

Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin

14 Jun 2020 19:22

Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen

(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus infection and say it should not be used as evidence for relaxing the UK's 2-metre physical distancing rule. Critics of the distancing advice, which states that people should keep at least 2 metres apart, believe it is too cautious. They seized on the research commissioned by the WHO, which suggested a reduction from 2 metres to 1 would raise infection risk only marginally, from 1.3% to 2.6%. - Guardian

28 May 2020 09:37